Category Archives: Business and Investments

Latest From Business and Investments

Congress, Media Focused on Biotech Food Labeling

food label

Media coverage of the biotech food labeling debate is at a fever pitch as the Safe and Accurate Food Labeling Act (H.R. 1599) is poised to see action on the floor of the House of Representatives this week. Among the highlights: Charles Conner, former United States Deputy Secretary of Agriculture and current president and CEO of the National Council of Farmer Cooperatives wrote an op-ed in RollCall: GMOs have been around for decades, helping farmers Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Biotech Companies Find Solutions through Synthetic Biology

scientist, lab

Several small companies presented their business models and milestones in the New and Innovative Technological Advances breakout session during the opening day of BIO’s World Congress. Each of the companies started out seeking an alternative to petroleum as a raw material for plastics and other polymers used in everyday household products. Additionally, these companies were united in finding unique solutions to scientific challenges through synthetic biology approaches. Eric Althoff, CBO of ten-year-old Arzeda, described his Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Letter of Support for 21st Century Cures Legislation

21st Century Cures Act

Today, BIO sent a letter to Reps. Boehner and Pelosi in support of the 21st Century Cures Act. In the letter, we applaud Chairman Upton, Ranking Member Pallone and Congresswoman DeGette’s efforts on H.R. 6., which takes important steps toward placing patients at the center of the drug development process. We also expressed support for precision medicine through genomics and regulatory science to help better understand the molecular basis of disease and develop precision therapies tailored to each Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

Emerging Therapeutic Company Investment and Deal Trends

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline. Some of the key findings Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

72263479

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,